{"nctId":"NCT03150589","briefTitle":"A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)","startDateStruct":{"date":"2018-03-14","type":"ACTUAL"},"conditions":["Age-Related Macular Degeneration"],"count":705,"armGroups":[{"label":"SB11 (Proposed ranibizumab biosimilar)","type":"EXPERIMENTAL","interventionNames":["Drug: SB11 (Proposed ranibizumab biosimilar)"]},{"label":"Lucentis (ranibizumab)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lucentis (ranibizumab)"]}],"interventions":[{"name":"SB11 (Proposed ranibizumab biosimilar)","otherNames":[]},{"name":"Lucentis (ranibizumab)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age â‰¥ 50 years\n2. Newly diagnosed, active subfoveal choroid neovascularisation (CNV) lesion secondary to AMD in the study eye\n3. BCVA of 20/40 to 20/200 in the study eye\n4. Written informed consent form\n\nExclusion Criteria:\n\n1. Any previous ITV anti-vascular endothelial growth factor (anti-VEGF) treatment to treat neovascular AMD in either eye\n2. Presence of CNV in either eye due to other causes, such as ocular histoplasmosis, trauma, multifocal choroiditis, angioid streaks, history of choroidal rupture or pathologic myopia\n3. Any concurrent macular abnormality other than AMD in the study eye","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Best Corrected Visual Acuity (BCVA)","description":"The VA was assessed using original series ETDRS charts or 2702 series number charts.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.26","spread":"0.51"},{"groupId":"OG001","value":"7.08","spread":"0.51"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Central Subfield Thickness (CST)","description":"The average retinal thickness in the central 1-mm area in the ETDRS grid (CST) was evaluated using (Optical Coherence Tomography) OCT","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-108.40","spread":"4.65"},{"groupId":"OG001","value":"-100.05","spread":"4.64"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":52,"n":350},"commonTop":["Nasopharyngitis","Intraocular pressure increased","Neovascular age-related macular degeneration","Hypertension","Visual acuity reduced"]}}}